HomeProductsBioactive CompoundsNeuronal SignalingAChRRevefenacin
Chemical structure of CAS 864750-70-9

Revefenacin

In Stock•Starting at $14 for 1 mg•Purity ≥ 98%
CAS No.864750-70-9
MDL No.MFCD28386316
MFC35H43N5O4
MW597.70
InChI KeyFYDWDCIFZSGNBU-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg98+%$14In Stock
5 mg98+%$31In Stock
10 mg98+%$45In Stock
25 mg98+%$74In Stock
50 mg98+%$124In Stock
100 mg98+%$208In Stock
250 mg98+%$350In Stock
1 g98+%$1251In Stock
5 g98+%$4994In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.864750-70-9
Product NameRevefenacin

Biological Targets

CHRM3

Associated Conditions

liver disease·chronic obstructive pulmonary disease·Airway obstruction·kidney disease
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.

Respiratory medicine • Vol. 153 • 2019
PMID: 31150963DOI: 10.1016/j.rmed.2019.05.010

The Role of Revefenacin in Chronic Obstructive Pulmonary Disease.

Cureus • Vol. 11, Issue 4 • 2019
PMID: 31245215PMC: PMC6559386DOI: 10.7759/cureus.4428

Revefenacin for the treatment of chronic obstructive pulmonary disease.

Expert review of clinical pharmacology • Vol. 12, Issue 4 • 2019
PMID: 30803279DOI: 10.1080/17512433.2019.1587292

Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.

Pharmacology research & perspectives • Vol. 6, Issue 3 • 2018
PMID: 29736245PMC: PMC5927803DOI: 10.1002/prp2.400

Documentation

Similar Products